Current Liabilities decreased faster than Gyre Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Gyre Therapeutics Inc 's Quick Ratio to 4.34, Quick Ratio remained below Gyre Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 201 other companies have achieved higher Quick Ratio than Gyre Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 793, from total ranking in the second quarter 2026 at 1007.

Explain Quick Ratio?
How much Cash & cash equivalents GYRE�s has?
What are GYRE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GYRE/financial-strength

https://api.csimarket.com/api/v1/companies/GYRE/fundamentals

https://api.csimarket.com/api/v1/companies/GYRE/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GYRE Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	24.89 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	43.53 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	4.34	Subscribe	Subscribe	Subscribe	Subscribe
GYRE's Total Ranking	# 793	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-5.17 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-0.11 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 202
Healthcare Sector	# 335
Overall Market	# 793

Quick Ratio Statistics
High	Average	Low
60.73	10.18	1.18
(Jun 30 2015)		(Mar 31 2023)

Financial Statements
Gyre Therapeutics Inc 's Current Liabilities	$ 20 Millions	Visit GYRE's Balance sheet
Gyre Therapeutics Inc 's Cash & cash equivalent	$ 86 Millions	Visit GYRE's Balance sheet
Source of GYRE's Sales		Visit GYRE's Sales by Geography

Cumulative Gyre Therapeutics Inc 's Quick Ratio

GYRE's Quick Ratio for the trailling 12 Months

GYRE Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	15.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	90.41 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.93	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3825	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	6.87 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GYRE Financial Strength Comparisons >> Go to Compare GYRE Quick Ratio to its Competitors

On the trailing twelve months basis GYRE Cash & cash equivalent soared by 43.53 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Gyre Therapeutics Inc 's Quick Ratio to 4.93, above GYRE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Gyre Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3688 to 3825.

Explain Quick Ratio?
How much Cash & cash equivalents GYRE�s has?
What are GYRE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 432
Healthcare Sector	# 882
Within the Market	# 3825

trailing twelve months Quick Ratio Statistics
High	Average	Low
17.87	4.02	0.85
(Dec 31 2018)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Obsidian Therapeutics, Inc.	11.77	$ 214.905 Millions	$ 18.264 Millions
Structure Therapeutics Inc	11.62	$ 1,244.661 Millions	$ 107.104 Millions
Kairos Pharma Ltd	11.60	$ 5.741 Millions	$ 0.495 Millions
Immunome Inc	11.27	$ 461.582 Millions	$ 40.966 Millions
Korro Bio Inc	11.06	$ 165.015 Millions	$ 14.923 Millions
Xenon Pharmaceuticals Inc	10.99	$ 950.798 Millions	$ 86.487 Millions
Newamsterdam Pharma Company N v	10.99	$ 628.242 Millions	$ 57.154 Millions
Vtv Therapeutics Inc	10.99	$ 77.164 Millions	$ 7.024 Millions
Abcellera Biologics Inc	10.85	$ 764.424 Millions	$ 70.473 Millions
Cogent Biosciences Inc	10.82	$ 791.134 Millions	$ 73.118 Millions
Bicycle Therapeutics Plc	10.57	$ 469.928 Millions	$ 44.459 Millions
Lipocine Inc	10.55	$ 21.455 Millions	$ 2.034 Millions
Cyclerion Therapeutics Inc	10.32	$ 456.221 Millions	$ 44.197 Millions
Lexicon Pharmaceuticals Inc	10.31	$ 183.203 Millions	$ 17.773 Millions
Adicet Bio Inc	10.28	$ 174.779 Millions	$ 16.996 Millions
An2 Therapeutics Inc	10.26	$ 64.400 Millions	$ 6.275 Millions
Pmv Pharmaceuticals Inc	10.15	$ 108.515 Millions	$ 10.689 Millions
Gri Bio Inc	9.94	$ 9.472 Millions	$ 0.953 Millions
Nuvectis Pharma inc	9.91	$ 140.707 Millions	$ 14.193 Millions
Renovorx Inc	9.76	$ 20.404 Millions	$ 2.091 Millions
Aprea Therapeutics Inc	9.52	$ 37.846 Millions	$ 3.975 Millions
Rezolute Inc	9.51	$ 89.999 Millions	$ 9.463 Millions
Atrium Therapeutics Inc	9.42	$ 232.421 Millions	$ 24.663 Millions
Opus Genetics Inc	9.05	$ 88.974 Millions	$ 9.832 Millions
Ibio inc	8.94	$ 76.654 Millions	$ 8.574 Millions
Ideaya Biosciences Inc	8.70	$ 838.541 Millions	$ 96.405 Millions
First Tracks Biotherapeutics Inc	8.60	$ 155.627 Millions	$ 18.090 Millions
Pepgen Inc	8.48	$ 104.805 Millions	$ 12.361 Millions
Medicinova Inc	8.47	$ 29.256 Millions	$ 3.456 Millions
Polaryx Therapeutics Inc	8.45	$ 8.440 Millions	$ 0.999 Millions

Date modified: 2026-11-07T13:17:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.